78/100 B+ · Low risk
No major risk flags in the public sources we cover Indicative TraceComp estimate from public sources — an automated indicator, not a credit decision, a completed due-diligence check, or a guarantee. Verify against the official register.

ℹ️ No matches surfaced in the limited public sources we cover (sanctions, screening, insolvency, control). This is an automated indicator — not an exhaustive check, a credit decision, or a guarantee, and absence of a match does not mean none exists. Verify against the official register.

Think this is wrong? This is an automated estimate — request a human review or correction.

OGD2 PHARMA

Active Simplified joint-stock company (SAS) Scientific research & development Active for 11 years

Simplified joint-stock company (SAS) · RC 807514237 · Active since 2014

B+

Overview

OGD2 PHARMA is a simplified joint-stock company (sas) registered in France, since 2014. The company operates in the scientific research & development sector. Its TraceComp score of 78 (B+) indicates solid fundamentals and low apparent risk. With 11 years of operations, the company has an established track record in its market.

Company Information

Registration Number
807514237
Legal Form
Simplified joint-stock company (SAS)
Registered
2014-10-28

Officers & Management

3 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
J•••-M••• L• D•••••• Officer Current
S•••••• R••••• Deputy statutory auditor Current
K••• S• Statutory auditor Current

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Patent Portfolio

Active patent holder. 6 patents · 6 active · 6 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • No financial filings on record — score derives from registry signals and sector context

Data Sources & Freshness

Data sourced from: bulk register.